Clinical Trial Detail

NCT ID NCT04013854
Title Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

melanoma

Therapies

Ipilimumab + Nivolumab

Nivolumab

Age Groups: adult senior

No variant requirements are available.